StreetInsider.com News Articles

Form 4 AGIOS PHARMACEUTICALS, For: Oct 21 Filed by: Gheuens Sarah

Fri, 23 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261023/27227895.html

Form 144 AGIOS PHARMACEUTICALS, Filed by: Gheuens Sarah

Thu, 22 Oct 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20261022/27223286.html

Form 144 AGIOS PHARMACEUTICALS, Filed by: Gheuens Sarah

Wed, 21 Oct 2026 17:32:00 -0400

si-local-file:///var/storage/secattach/20261021/27217373.html

Agios Pharma (AGIO) Reiterated at Overweight by Cantor Fitzgerald as PDUFA Date Approaches

Thu, 15 Oct 2026 07:28:56 -0400

Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Agios Pharma (NASDAQ: AGIO).

The analyst commented, "The drug's PDUFA date is just around the corner (November 1st), and Agios has continued to voice confidence in its approval...management sounded not only confident in approval (potentially without need for a REMS program), but also confident in rapid commercial adoption. We think this launch could best investor expectations much like what happened in thalassemia, with the one difference being that SCD is a much larger opportunity."

For an analyst ratings summary and ratings history on Agios Pharma click here. For more ratings news

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET

Thu, 08 Oct 2026 07:00:00 -0400

CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, November 5, 2026, at 8:00 a.m. ET to report its third quarter 2026 financial results and business highlights.

The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET

Thu, 08 Oct 2026 07:00:00 -0400

Agios Pharma (AGIO) PT Lowered to $37 at Truist Securities

Wed, 07 Oct 2026 07:13:00 -0400

Truist Securities analyst Greg Renza lowered the price target on Agios Pharma (NASDAQ: AGIO) to $37.00 (from $39.00) while maintaining a Buy rating.

TD Cowen Assumes Agios Pharma (AGIO) at Buy

Sat, 22 Aug 2026 07:55:17 -0400

TD Cowen analyst Jon Thome assumes coverage on Agios Pharma (NASDAQ: AGIO) with a Buy rating.

For an analyst ratings summary and ratings history on Agios Pharma click here. For more ratings news on Agios Pharma click here.

Shares of Agios Pharma closed at $33.09 yesterday.

Agios Pharma (AGIO) Reiterated at Overweight by Cantor Fitzgerald on Thalassemia Opportunity

Mon, 17 Aug 2026 07:54:11 -0400

Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Agios Pharma (NASDAQ: AGIO).

The analyst commented, "The FDA granted mitapivat's sNDA priority review and indicated to Agios that there is no need for an AdComm. Yet despite a seemingly high probability of approval in a sizable rare-disease indication that features very substantial unmet need, few investors appear willing to give AGIO much, if any, value for this opportunity. AGIO trades with an EV of just ~$1B. We think this valuation is fully supported by mitapivat's thalassemia opportunity, which we estimate at ~$500M in the US and ~$800M worldwide. Recall, Agios

Agios Pharma (AGIO) PT Raised to $34 at JPMorgan

Fri, 07 Aug 2026 08:57:04 -0400

JPMorgan analyst Tessa Romero raised the price target on Agios Pharma (NASDAQ: AGIO) to $34.00 (from $31.00) while maintaining a Neutral rating.

Form 4 AGIOS PHARMACEUTICALS, For: Aug 04 Filed by: Gheuens Sarah

Thu, 06 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260806/26884174.html

Form 4 AGIOS PHARMACEUTICALS, For: Aug 04 Filed by: Gheuens Sarah

Thu, 06 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260806/26884174.html

Form 144 AGIOS PHARMACEUTICALS, Filed by: Gheuens Sarah

Tue, 04 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260804/26866284.html

Form 144 AGIOS PHARMACEUTICALS, Filed by: Gheuens Sarah

Tue, 04 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260804/26866284.html

Form SCHEDULE 13G/A AGIOS PHARMACEUTICALS, Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Mon, 03 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260803/26854496.html

Form SCHEDULE 13G/A AGIOS PHARMACEUTICALS, Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Mon, 03 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260803/26854496.html

Agios Pharma (AGIO) PT Lowered to $39 at Truist Securities

Fri, 31 Jul 2026 07:09:26 -0400

Truist Securities analyst Greg Renza lowered the price target on Agios Pharma (NASDAQ: AGIO) to $39.00 (from $41.00) while maintaining a Buy rating.

Form 10-Q AGIOS PHARMACEUTICALS, For: Jun 30

Thu, 30 Jul 2026 09:56:00 -0400

si-local-file:///var/storage/secattach/20260730/26840623.html

Form 10-Q AGIOS PHARMACEUTICALS, For: Jun 30

Thu, 30 Jul 2026 09:56:00 -0400

si-local-file:///var/storage/secattach/20260730/26840623.html

Agios Pharma (AGIO) Misses Q2 EPS by 4c

Thu, 30 Jul 2026 06:33:37 -0400

Agios Pharma (NASDAQ: AGIO) reported Q2 EPS of ($1.69), $0.04 worse than the analyst estimate of ($1.65). Revenue for the quarter came in at $44.74 million versus the consensus estimate of $26.57 million.

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.

Form 8-K AGIOS PHARMACEUTICALS, For: Jul 30

Thu, 30 Jul 2026 06:33:00 -0400

si-local-file:///var/storage/secattach/20260730/26838104.html

Form 8-K AGIOS PHARMACEUTICALS, For: Jul 30

Thu, 30 Jul 2026 06:33:00 -0400

si-local-file:///var/storage/secattach/20260730/26838104.html

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 30 Jul 2026 06:30:00 -0400

Mitapivat (PYRUKYND® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025
Strong U.S. commercial launch of AQVESME in thalassemia, with 442 cumulative prescriptions written as of June 30, 2026
sNDA for mitapivat granted FDA Priority Review in sickle cell disease with PDUFA goal date of November 1, 2026
Diversified and expanded late-stage pipeline with licensing of cevidoplenib for immune thrombocytopenia and advancement of AG-236 into Phase 2/3 development for polycythemia vera
$964.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026; well

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 30 Jul 2026 06:30:00 -0400

Mitapivat (PYRUKYND® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025
Strong U.S. commercial launch of AQVESME in thalassemia, with 442 cumulative prescriptions written as of June 30, 2026
sNDA for mitapivat granted FDA Priority Review in sickle cell disease with PDUFA goal date of November 1, 2026
Diversified and expanded late-stage pipeline with licensing of cevidoplenib for immune thrombocytopenia and advancement of AG-236 into Phase 2/3 development for polycythemia vera
$964.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026; well

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 30 Jul 2026 06:30:00 -0400

Mitapivat (PYRUKYND® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025
Strong U.S. commercial launch of AQVESME in thalassemia, with 442 cumulative prescriptions written as of June 30, 2026
sNDA for mitapivat granted FDA Priority Review in sickle cell disease with PDUFA goal date of November 1, 2026
Diversified and expanded late-stage pipeline with licensing of cevidoplenib for immune thrombocytopenia and advancement of AG-236 into Phase 2/3 development for polycythemia vera
$964.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026; well